Vol. 5 No. 6S (2011)

Vol. 5 No. 6S (2011)

Published: 2011-12-30

The importance of comorbidity and the usefulness of therapeutic early shift in the management of CML patients

Fabio Stagno

3-4
- PDF

Efficacy of nilotinib as third-line treatment in a patient with very late Chronic Myeloid Leukemia and a possibile cardiologic contraindication

Ester Maria Orlandi, Sara Redaelli

5-9
- PDF
Nilotinib early switch efficacy in non-optimal responder CML patient after first line imatinib treatment

Ferdinando Porretto

11-16
- PDF
Nilotinib is effective and well tollerate in patients with multiple comorbidities

Carmen Fava, Marco Fizzotti, Giuseppe Saglio, Giovanna Rege-Cambrin

17-21
- PDF
Early switch to nilotinib in a case of non-optimal response to imatinib

Alessandra Iurlo, Tommaso Radice, Chiara De Philippis, Manuela Zappa, Mauro Pomati, Agostino Cortelezzi

23-26
- PDF